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ABSTRACT
DNA topoisomerase II (topo II) changes DNA topol-
ogy by cleavage/re-ligation cycle(s) and thus con-
tributes to various nuclear DNA transactions. It is
largely unknown how the enzyme is controlled in a
nuclear context. Several studies have suggested that
its C-terminal domain (CTD), which is dispensable for
basal relaxation activity, has some regulatory influ-
ence. In this work, we examined the impact of nuclear
localization on regulation of activity in nuclei. Specif-
ically, human cells were transfected with wild-type
and mutant topo II tagged with EGFP. Activity at-
tenuation experiments and nuclear localization data
reveal that the endogenous activity of topo II is cor-
related with its subnuclear distribution. The enzyme
shuttles between an active form in the nucleoplasm
and a quiescent form in the nucleolus in a dynamic
equilibrium. Mechanistically, the process involves a
tethering event with RNA. Isolated RNA inhibits the
catalytic activity of topo II in vitro through the inter-
action with a specific 50-residue region of the CTD
(termed the CRD). Taken together, these results sug-
gest that both the subnuclear distribution and activ-
ity regulation of topo II are mediated by the interplay
between cellular RNA and the CRD.
INTRODUCTION
Type II DNA topoisomerases (topos II) catalyze intercon-
version of DNA’s topological states by swapping the spa-
cial position of two segments of duplex DNA (1). This is
achieved through a catalytic cycle composed of multiple
steps that are highly concerted (2). Structural basis for the
reaction comes from three mobile ‘gates’ that are formed
between two identical subunits associated head-to-head ori-
entation (3) (see Supplementary Figure S1). Two segments
of DNA enter from theN-terminal gate (N-gate) whose clo-
sure and opening is controlled by binding and hydrolysis of
adenosine triphosphate (ATP), respectively.
While invertebrates have only one form of topo II, ver-
tebrates have two isoforms ( and ) encoded by distinct
genes (4–6). Although the two isoforms possess very simi-
lar basic structure andmode of reaction, they are clearly dif-
ferent in several aspects. Topo II relaxes positively super-
coiled DNA more readily than negative supercoils in vitro
(7). Expression of topo II is restricted to proliferating cells
and is regulated in a cell cycle-dependent manner (8,9). It
plays a critical role in the decatenation of entangled sister
chromatids before segregation, thus being essential for cell
proliferation. In contrast, topo II appears to play more
specialized roles in cellular physiology. Topo II is indis-
pensable for gene regulation in the final stage of neuronal
differentiation when the enzyme shows elevated expression
(10–13). In immortalized cell lines, however, its expression
is de-regulated to become constitutive and even dispensable
for cell survival (8,14).
Amino acid sequence of topo II isoforms is highly ho-
mologous each other (80–90% similarity) except for ∼400
residues in the C-terminal domain (CTD). Whether the dif-
ference in CTD sequence can explain the differential be-
havior of topo II isoforms is an obvious question, which
is not fully answered. Remarkably, CTD is dispensable for
the basal activity of topo II (15). There has been little in-
sight from structural studies since the domain is an intrin-
sically disordered region with little higher-order structure
(16). Several reports have already addressed the functional
ambiguity of CTD. Specifically, comparison between topo
II wild-type (WT) and CTD-truncated mutant revealed
that CTD confers preference to positive supercoils (7). It
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would be reasonable to assume that CTD has some regula-
tory role not only in the catalytic reaction per se, but also
in living cells. The latter may be complex due to unknown
interactive factors. The primary function of CTD would be
to confine the enzyme to the nucleus as multiple nuclear lo-
calization signals (NLSs) have been located in CTD (17–
19). Experiments where the CTDs were swapped between
the two isoforms exhibited the importance of CTD in the
isoform-specific functioning in vivo (20).
Most nuclear proteins localize to certain subnuclear re-
gions because they are either in an operational mode or in a
transient holding pattern. During M-phase, nucleoplasmic
proteins redistribute to daughter cells by associating with
chromosomes, while others diffuse out through the cyto-
plasm after the breakdown of nuclear membrane. Nuclear
dynamics of topo II isoform distribution has been evalu-
ated in a cellular context using photobleaching (21). The re-
sults showed clearly that in mitosis topo II migrates with
chromosomes, whereas topo II becomes cytoplasmic. In
interphase, both are concentrated in nucleoli in a dynamic
process, as attested by the rapid movement to nucleoplasm
following treatment with topo II-specific poisons such as
etoposide, which covalently traps the enzyme on genomic
DNA.
Despite the recent progress in this area, regulation of
topo II in the nuclear milieu remains unsettled. One issue
in particular is how topo II operates catalytically in an en-
vironment replete with RNA, given that RNA is strongly
inhibitory at least in vitro (22,23). We have shown recently
that the RNA inhibition is neutralized by an nucleoplasmic
RNA-binding protein hnRNPU/SAF-A/SP120 (23), thus,
providing a rational built-in mechanism for activity regula-
tion. In the present study, we examined the mechanism of
topo II activity regulation by analyzing the dynamics of
subnuclear localization in response to activity changes. Re-
sults show that topo II shuttles between nucleoplasm and
nucleolus in a dynamic equilibrium that is determined by
its residence time on nuclear DNA.We also investigated the
roles of CTD in vitro using immobilized topo II on beads
and successfully identified a subdomain in CTD that is re-
quired for the susceptibility to RNA, which suggests that
RNA is an innate regulator of topo II.
MATERIALS AND METHODS
Plasmid construction
The plasmid pFlag-top2b encoding the full-length rat topo
II (1614 amino acids) with Flag sequence tagged at the
N-terminus was constructed. The original topo II cDNA
clone (AB262979) was amplified with primers contain-
ing restriction overhangs (Not I/Sma I) that are listed in
the supplementary file (Supplementary Table S1). A high-
fidelity DNA polymerase, Phusion Hot Start II (Thermo
Scientific), was used throughout. The polymerase chain
reaction (PCR) product was inserted in frame between
the Not I/Sma I sites of pFlag-CMV-2 expression vector
(Sigma-Aldrich). To obtain Flag-fused C-terminal trunca-
tion mutants (CTD, CTD’), the pFlag-top2b plasmid
was amplified with primers listed in Supplementary Ta-
ble S1 and the products were inserted into pFlag-CMV-
2 between Not I/Sma I sites. To construct pFlag-top2b
(CRD) expression plasmid, a C-terminal portion of topo
II (CTD’; #1251–1614) was PCR amplified from pFlag-
top2b with primers containing restriction overhangs (Sma
I/Sma I). The PCR product was then inserted at the Sma I
site of the pFlag-top 2b (CTD) expression plasmid and a
transformed colony containing the insert in correct orienta-
tion was selected by colony PCR using forward primer (5′-
GTCTCTATGGTCTCTTAC-3′) and reverse primer (5′-
TCCCCCGGGCTCCTTTTTCTCCCTTTT-3′).
The plasmid pEGFP-top2b that encodes the full-length
rat topo II with enhanced green fluorescent protein
(EGFP) sequence fused at the C-terminus was constructed.
The pFLAG-top2b plasmid was PCR amplified with
primers containing restriction overhangs (Xho I/Sma I)
and the product was inserted in frame between the Xho
I/Sma I sites of pEGFP-N1 expression vector (Clontech).
Amino acid substitution mutants of topo II (G173I,
L178F and Y814S) were prepared using QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent) with the pEGFP-
Top2b plasmid as a template and with primers containing
the desired mutation (underlined in Supplementary Table
S1).
To express proteins with Flag-tag at the N-terminus
and EGFP-tag at the C-terminus, pFlag-CMV-2-EGFP ex-
pression vector was constructed. We first obtained EGFP
cDNA from pEGFP-N1 vector by PCR amplification
with a primer pair (sense, 5′-GGGAATTCTCGAGTAG
ATCTGCCGGTCGCCACCATGGTG-3′; antisense, 5′-
CGGGATCCCGCTTTACTTGTACAGCTC-3′) contain-
ing Eco RI or Bam HI overhangs (underlined). The EGFP
cDNA was then inserted in frame between the Eco RI/Bgl
II sites of the pFlag-CMV-2 vector. DNA fragments en-
coding the full-length or domain mutants of topo II were
PCR amplified with primers containing restriction over-
hangs (Not I/Sma I or Sma I/Sma I) from pFlag-top2b and
subcloned into the pFlag-CMV-2-EGFP vector.
All the constructs used in this work were sequenced to
confirm the absence of unintended mutations.
Cell culture and transfection
The human embryonal kidney cell line HEK293E (desig-
nated HEK hereafter), a rat fibroblast-like cell line (Rat-1)
and a mouse neuroblastoma cell line (Neuro 2a) cells were
grown at 37◦C in a humidified atmosphere of 5% CO2 in
a Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich) supplementedwith 10% fetal calf serum (FCS) and
100 g/ml kanamycin sulfate.
For ATP depletion studies, cells were washed with phos-
phate buffered saline (PBS), and incubated in glucose-free
DMEM (catalog no. 11966–025; GIBCO BRL) containing
10 mM sodium azide, 6 mM 2-deoxy-D-glucose, 100 g/ml
kanamycin sulfate and 10% FCS (hereafter referred to as
‘ATP depletion medium’) for times indicated in the figure
legends (24). Cellular ATP was quantified by a luciferin–
luciferase-based ATP assay kit (Wako, Japan) according to
the manufacturer’s instructions.
For in situ digestion of cellular RNA or DNA, cells
were permeabilized with 50 g/ml digitonin in 20 mM
HEPES-KOH (pH 7.3), 110 mMKOAc, 5 mMMgCl2 and
2 mM dithiothreitol for 5 min at 37◦C, followed by diges-
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tion with 0.4 mg/ml RNase A (Qiagen) or 1.4 U/l DNase
I (InvitrogenTM) in 50 mM HEPES-NaOH (pH 7.4), 120
mM NaCl and 10 mMMgCl2 for 20 min at 37◦C.
For cell transfection, HEK cells (2 × 105 cells/35-mm
dish) were cultured for 24 h and then incubated with 3 l
of FuGENE 6 Transfection Reagent (Promega), and 1 g
of pFlag-CMV-2, pEGFP-N1 or pFlag-CMV-2-EGFP ex-
pression vectors harboring full-length or mutant topo II
cDNA. After 24 h, cells were subjected to analyses.
Immunocytochemistry
Cells were grown on 13-mm round coverslips immersed in
DMEM with 10% FCS and 100 g/ml kanamycin sulfate.
Cells at subconfluency were fixed with 4% paraformalde-
hyde (PFA) in PBS kept at 37◦C or on ice beforehand as
indicated in figure legends, permeabilized then with 0.3%
Triton X-100 in PBS and blocked with 10% goat serum in
PBS containing 0.3% Triton X-100 (TPBS). After incuba-
tion with primary antibodies diluted in PBS supplemented
with 1% goat serum, sections were washed with PBS, fol-
lowed by incubationwith fluorescent conjugates of goat sec-
ondary antibodies in PBS (9,10). Cells were finally stained
for DNA with 0.25 g/ml 4′, 6-diamidino-2-phenylindole
(DAPI) in PBS.
Fluorescence microscopy
To capture images of living cells, HEK cells express-
ing EGFP-tagged recombinant proteins on 35-mm glass-
bottomed dishes were examined under an inverted fluores-
cencemicroscope equippedwithApoTome device (Axiovert
200M; Carl Zeiss) and a cooled CCD camera (AxioCam
MRm) using Axiovision 4.01 software (Zeiss).
For time-lapse imaging, the glass-bottomed dishes with
HEK/topo II-EGFP cells in 2 ml of growth medium were
placed into an on-stage heating and cooling chamber (Tem-
perable Insert P S1, Carl Zeiss) equipped with F25-ME
Refrigerated/Heating Circulator (Carl Zeiss), and images
were recorded at 1-min intervals for 60 min in the environ-
mental chamber ensuring a constant change of temperature.
Fluorescence recovery after photobleaching (FRAP)
analysis of living cells was performed at either 37 or
18◦C with a confocal microscope (FV-1000; Olympus; op-
erated by the built-in software version 2.1.1.4) equipped
with a CO2-controlled on-stage heating chamber using a
PLAPON 60XOSCNA 1.4 oil immersion lens. Images were
taken before (10 images) and after (120 images) bleach-
ing of a circular area of 1-m diameter at 100% 488-nm
laser transmission with four iterations. The imaging scans
were acquired with a laser power attenuated to 0.1% of
the bleached intensity using settings of 205 ms/frame; 2
s/pixel; pinhole 300 m (25). Binding kinetics was ana-
lyzed as described (26).
Protein expression and purification
To express Flag-tagged proteins for in vitro experiments,
HEKcells grown to subconfluency on 100-mmdishes (1.2×
106 cells/dish) were transfected with 3 g of the construct
plasmids using FuGENE 6 and cultured for 3 days. Cells
were lysed on ice in 1 ml/dish of ice-cold high salt buffer
(HSB) consisted of 50 mMHEPES-NaOH (pH7.4), 1 mM
ethylenediaminetetraacetic acid (EDTA), 500 mM NaCl,
1 mM dithiothreitol, 0.1% NP-40 and Protease Inhibitor
Cocktail (PIC, EDTA-free; Roche). Clear lysates were pre-
pared by repeated centrifugation. Immunoprecipitationwas
performed at 4◦C for 2 h with Dynabeads Protein G that
had been pre-coated with anti-tag antibodies. After incu-
bation, the beads were washed three times with HSB, sus-
pended in 50 mMTris–HCl (pH 8.0), 120 mMKCl, 10 mM
MgCl2, 1 mM dithiothreitol, 0.5 mM EDTA, PIC and 50%
glycerol. The beads suspension was stored at −80◦C until
use.
To release Flag-tagged proteins from the Dynabeads, the
protein-bound beads were incubated with 150 g/ml 3×
Flag peptide (Sigma) in 50 mMTris–HCl (pH 8.0), 120 mM
KCl, 10 mM MgCl2, 1 mM dithiothreitol, 0.5 mM EDTA
and PIC for 30min on ice. The released proteins were frozen
quickly in liquid N2 and stored at −80◦C until use.
Protein concentrations of purified fractions were deter-
mined by densitometric scanning of SYPRO Ruby-stained
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gel bands using bovine serum albumin
(BSA) as a standard.
Procedures that involve western blotting
Western blotting was carried out as described (11). Cells
grown on culture dishes were lysed directly in SDS-PAGE
sample buffer (50 mM Tris–HCl: pH 6.8, 2% SDS, 1.25%
2-mercaptoethanol, 250 mM sucrose, 0.0025% bromophe-
nol blue), subjected to 6.5% SDS-PAGE and transferred
to a polyvinylidene difluoride (PVDF) membrane. Protein-
blottedmembranes were incubatedwith anti-topo IImon-
oclonal antibody (clone 3B6, 1.5 g/ml) (10) and then with
horseradish peroxidase-conjugated second antibody (KPL)
according to standard procedure. The peroxidase activity
was detected by a chemiluminescencemethod using an ECL
kit (GE Healthcare) and recorded on VersaDoc MP 5000
Imaging Systems (Bio-Rad). Protein bands were quantified
by densitometry.
For band depletion assay, cells grown on 35 mm-culture
dishes were incubated with 200 M etoposide (VP-16) in
DMEM for 30 min at 37◦C in a humidified atmosphere of
5% CO2 to stabilize topo II–DNA cleaved complex. The
etoposide-treated cells were lysed directly in 100 l of SDS-
PAGE sample buffer and 10 l-aliquots were subjected to
western blot analyses.
Relaxation assay
Relaxation of supercoiled pUC18 (form I) DNA by im-
munopurified Flag-topo II, either WT or a deletion mu-
tant, was carried out for 30 min at 30◦C in 10 l of reaction
mixture containing 5 or 50 ng DNA, 50 mM Tris–HCl (pH
8.0), 120 mM KCl, 10 mM MgCl2, 0.5 mM dithiothreitol,
0.5 mM EDTA, 0.5 mM ATP and 30 g/ml BSA, unless
stated otherwise (27). Reaction products were treated with
1% SDS and 100 g/ml proteinase K at 55◦C for 30 min
before applying to 1% agarose gel electrophoresis. Topoiso-
mer DNA bands were visualized by staining with 1/10 000x
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SYBR Green I (Takara Bio, Japan) or 0.5 g/ml ethidium
bromide. Fully supercoiled DNA substrates that remained
unrelaxed after the reaction were quantified by densitome-
try.
For relaxation of supercoiled DNA in ‘on-bead assay’,
the Flag-tagged enzyme protein immobilized on the Dyn-
abeads through anti-Flag antibody was incubated with sub-
strate DNA as described above. After reaction, DNA prod-
ucts were fractionated immediately into enzyme-bound and
free in solution by magnetic separation and treated with 1%
SDS and 100 g/ml proteinase K prior to electrophoresis
on 1% agarose gel.
RNA-binding assay
RNA was purified from HEK cells by using RNeasy
Mini kit (Qiagen). This total RNA was separated into
Poly(A)+ RNA and Poly(A)− RNA fractions using Dyn-
abeads mRNA Purification Kit (InvitrogenTM). Purified
RNAs were incubated at 30◦C for 30 min with 80 fmol
Flag-tagged proteins (WT topo II or deletion mutants)
immobilized on the Dynabeads in 10 l of binding mix-
ture containing 50 mM Tris–HCl (pH 8.0), 120 mM KCl,
10 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM EDTA, 30
g/ml BSA and 4U RNase inhibitor from porcine liver
(Takara Bio). Following magnetic separation, bead-bound
RNA (bound to topo II) and free RNA in solution were
quantified directly using Quant-iTTM RiboGreen RNAAs-
say Kit (InvitrogenTM) and GENios multi-detection mi-
croplate reader (Tecan).
DNA-binding assay
Flag-tagged proteins (80 fmol of WT topo II or deletion
mutants) were immobilized on Dynabeads through anti-
Flag antibody and incubated with 5 ng pUC18 plasmid
DNA (supercoiled or linear) in 10 l of the RNA-binding
mixture stated above (but without RNase inhibitor). Fol-
lowing magnetic separation, bead-bound DNA (bound to
topo II) and free DNA in solution were treated with
1% SDS and 100 g/ml proteinase K. DNAs were elec-
trophoresed on 1% agarose gel, followed by visualization
with SYBR Green I and quantification by densitometry.
RESULTS
Relocation of topo II in interphase nuclei
The catalytic activity of topo II in neuronal cells remains
quite high during the terminal differentiation when the en-
zyme distributes in both nucleoplasm and nucleoli. As the
cells develop to mature neurons, it shows decreased activity
in vivo, which is measured by its cross-linking to genomic
DNA following etoposide treatment. In concert with this
change, the enzyme accumulates in nucleoli (9,10). These
results suggest that a subpopulation of topo II is engaged
in catalytic action by interacting with DNA in the nucleo-
plasm and another located in nucleoli has little or no access
to DNA. In cultured cells, the nuclear distribution of topo
II detected by immunostaining varies depending on cell
types and preparation methods (17,21,28,29). Since topo
II in interphase nuclei of living cells is quite mobile (21),
cellular conditions at the time of fixation can be a critical
factor for the variable localization.
We used three different cell lines (HEK293, Rat-1, Neuro
2a) to assess the effects of temperature, topo II inhibition
and cellular ATP content on distribution (Figure 1). Nucle-
oli were identified by double-immunostaining with an an-
tibody against nucleolin (9). To our surprise, the nuclear
distribution of topo II differed dramatically depending on
the temperature of fixation. When cells were fixed at 37◦C,
topo II distributed throughout the nucleus with remark-
able enhancement in nucleoli in all three cell types (Fig-
ure 1A). When cells were fixed on ice, however, the sig-
nal in nucleoli decreased substantially and the nucleoplas-
mic stain increased reciprocally, co-localizing with DAPI-
staining signal (Figure 1B). A similar relocation of the en-
zyme was observed by treating the cells with ICRF-193
(Figure 1C), a catalytic inhibitor of type II topos that sta-
bilizes the closed clamp conformation around target DNA
during the catalytic reaction (30). In both low temperature
and ICRF treatments, some topo II signals in nucleoplasm
co-localizedwith heterochromatic regions (chromocenters),
which is most obvious in mouse Neuro 2a cells. Similar pat-
tern of localization was observed by treating mouse cells
with etoposide (VP-16), a topo II poison that stabilizes
the enzyme–DNA covalent complexes (31). As topo II re-
quires ATP for its catalytic activity (32), cells were depleted
of ATP to see whether its nuclear distribution changes. The
treatment abolished nucleoplasmic topo II and essentially
all fluorescence was localized to the nucleolar region (Fig-
ure 1D). These results are in good agreement with the no-
tion that the catalytically active topo II is largely nucleo-
plasmic, while the nucleolar form is inactive.
Dynamic relocation of topo II-EGFP between nucleoplasm
and nucleoli in living cells
To further investigate the relationship between the en-
zyme activity and nuclear distribution in a cellular con-
text, EGFP-fused topo II was transiently expressed in
HEK293 cells. As with endogenous enzyme (Figure 1A and
C), EGFP signals in live cells were concentrated in nucle-
oli, andmigrated to nucleoplasmupon ICRF-193 treatment
(Figure 2B, leftmost column). When cellular ATP levels
were reduced to<10% by sodium azide and 2-deoxyglucose
for the times indicated (Figure 2A), nucleoplasmic EGFP
signals were again strongly reduced. Concurrently, topo II
was clearly located in nucleolar regions (Figure 2B, upper
panel). In the ATP-depleted cells, the nucleolar signal did
not re-distribute to nucleoplasm upon ICRF-193 treatment
(Figure 2B, lower panels), suggesting that inactive enzyme
remains in the nucleoli. The process was rapid and com-
pletely reversible as subsequent recovery of cellular ATP
level increased EGFP signals in nucleoplasm back to basal
levels and restored the effect of ICRF-193 (Figure 2A and
B, rightmost column).
Molecular mechanism underlying the relocation of topo
II from nucleoli to nucleoplasm at lowered temperature
(Figure 1B) was investigated by time-lapse fluorescence mi-
croscopy and FRAP. Medium temperature was lowered
continuously from 37 to 15◦C in 30 min, and then brought
back to 37◦C in the next 30 min. Nuclear distribution of
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Figure 1. Subnuclear localization of topo II under different conditions. Topo II and nucleolin (as a nucleolus marker) were immunostained with cross-
reactive antibodies in human (HEK293), rat (Rat-1) and mouse (Neuro 2a) cell lines under four different conditions. Topo II (green) and nucleolin
(magenta) are shown together with merged images and DNA (DAPI). Scale bars, 5 m. (A) Cells were fixed with PFA at 37◦C. (B) Cells were fixed with
PFA at 0◦C. (C) Cells were first treated with 30 M ICRF-193 for 15 min and then fixed at 37◦C. (D) Cells were first treated with 10 mM sodium azide
and 6 mM 2-deoxy-D-glucose for 40 min and then fixed at 37◦C.
topo II-EGFP was recorded in real time and shown in the
upper panel (Figure 3A). The nucleolar signal faded out at
temperatures below 20◦C (20-min incubation) and recov-
ered by the time when the temperature reached 37◦C (60-
min incubation), indicating that the temperature-induced
relocation process is not only rapid, but also reversible. We
next compared the motility of nucleoplasmic and nucleolar
topo II-EGFP by FRAP under different temperatures. As
shown inFigure 3B, the recovery of fluorescence in bleached
areas was notably faster in nucleoplasm than in nucleoli at
37◦C (binding time = 1.38 ± 0.64 and 3.75 ± 0.98 s, re-
spectively), in good agreement with a previous report (21).
At 18◦C, however, the mobility of nucleoplasmic topo II-
EGFP dropped remarkably. In contrast, the nucleolar mo-
bility change was relatively small (binding time = 7.61 ±
1.83 and 5.89± 2.53 s, respectively). Thus, the accumulation
of nucleoplasmic topo II at the lower temperature may be
due to increased binding times or residence times in the nu-
cleoplasm.
To correlate nucleoplasmic-nucleolar dynamics with cat-
alytic activity, we fractionated free and enzyme-bound
DNA using immobilized topo II on magnetic beads (on-
bead assay). Topo II protein, Flag-tagged at the N-
terminus, was expressed inHEK cells and pulled down onto
the beads coated with anti-Flag antibody. Washed beads
were used for relaxation of supercoiled plasmid DNA. At
37◦C, fully relaxed DNAwas released from the enzyme and
recovered in unbound fraction, whereas partially relaxed
DNA remained on the beads (Figure 3C, left panel). The
beads-bound fraction reflects the DNA directly bound to
topo II since control beads without enzyme or antibody
do not bind DNA (data not shown). When the reaction
temperature was lowered to 15◦C, more plasmid DNA re-
mained on the beads (Figure 3C, right panel). At 0◦C, es-
sentially all partially relaxed DNA was bound to the en-
zyme and unrelaxed substrate was recovered in unbound
fraction. At 15◦C, the DNA in unbound fraction is fully
relaxed. The relative difference in the positions of topoiso-
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Figure 2. Topo II shuttles between nucleoplasm and nucleoli depending
on the cellular content of ATP. At time zero, culture medium was changed
to depletion medium containing sodium azide and 2-deoxy-D-glucose. Af-
ter 40 min, the medium was replaced with normal medium and contin-
ued to incubate at 37◦C (indicated by arrow). (A) Time course of the rel-
ative cellular ATP levels after depletion/recovery treatments. Cells were
removed at the time points indicated and cellular ATP was determined by
fluorometry and plotted in the graph. Data points represent mean/SD (n
= 3). Regression curves were drawn using a software, GraphPad Prism 5
(logistic curve fitting). (B) HEK cells were transfected with pEGFP-top2b
and after 24 h, the ATP depletion/recovery procedure was done as in (A).
Fluorescence micrographs of nuclei taken at the indicated times are shown
in the upper row (control). Shown in the lower row are cells treated with 30
M ICRF-193 for 15 min at the times indicated. Note that ICRF-induced
relocation of topo II does not occur under low ATP condition. Scale bar,
5 m.
mer bands between 37 and 15◦C is due to the temperature-
dependent change in the writhe, which was confirmed by
electrophoresis in the presence of ethidium bromide and by
time course studies at each temperature (results not shown).
These findings recapitulate our in vivo observations, specifi-
cally, that the catalytic cycle slows as temperature decreases
and thus a higher proportion of topo II would be retained
on chromatin DNA in the nucleoplasm.
We further observed differential nuclear localization of
topo IImutants with single amino acid changes that cause
functional defects (Figure 4A). The constructs were fused
with EGFP to track their nuclear location and to unam-
biguously discriminate from the endogenous WT enzyme.
Activity measurements using a band depletion assay with
transfected cells confirmed expected properties of these mu-
tants (Figure 4B). This assay is based on the fact that pro-
tein bands for catalytically active topo II on immunoblots
are reduced after treating cells with a topo II poison such as
VP-16. The reduction is due to formation of covalent topo
II/DNA complexes (33).
The Gly-164 to Ile mutation in human topo II disrupts
the ATP binding and hydrolysis activities (34). Therefore,
Gly-173 in rat topo II, the counterpart residue of Gly-164
of human , was altered to Ile (G173I). As shown in Figure
4B, the EGFP-fused G173I mutant (GI-EGFP) expressed
in HEK cells did not possess enzymatic activity. The inac-
tive mutant GI-EGFP remained in nucleolar region both in
the absence and presence of ICRF-193 (44.5 ± 8.3 and 39.3
± 7.4%, respectively), as compared to WT-EGFP (36.2 ±
7.9 versus 8.2 ± 2.8%, Figure 4C).
Mutation of Leu-178 to Phe in rat topo II (L178F) con-
verted the enzyme to an ICRF-193-resistant form just like
the human topo II counterpart, L169F (35). Although
LF-EGFP was enzymatically active (Figure 4B), it was re-
sistant to ICRF-193 (Figure 4C), as it accumulated in nucle-
oli in the presence or absence of ICRF-193 (37.1 ± 7.9 and
40.4 ± 7.1%, respectively). The resistance of L178F/LF-
EGFP toward ICRF-193 was also confirmed by in vitro ac-
tivity assays (results not shown).
Tyr-814 of rat topo II is an essential residue for the ac-
tivity. The Tyr to Ser mutant (Y814S) was incompetent in
the formation of a DNA cleavage complex (Figure 4B) as
in the previously characterized human topo II mutant,
Y805S (36). Figure 4C shows that YS-EGFP is largely non-
nucleolar, even in the absence of ICRF-193 (8.3 ± 2.4%
in nucleoli). Treatment of the cells with ICRF-193 did not
change the distribution (8.3 ± 2.5% in nucleoli). Since the
active site tyrosine mutant of human topo II (Y805S) was
shown to be able to close theN-gate (36), nucleoplasmicYS-
EGFP is likely due to trapping by the N-terminal clamp.
Association of topo II with RNA in nucleoli
Although immobile topo II molecules are virtually absent
in living cells, the enzyme is not as freely diffusible as free
EGFP (21). A simple model analysis for nuclear topo II
distribution showed that a higher proportion of the enzyme
is ‘bound’ as compared to ‘free’ in nucleolus, as well as in
nucleoplasm (37). In addition to this, except for the Y814S
mutant, almost half of topo II located in nucleoli in living
cells (Figure 4C), andmotility of theWT enzyme in nucleoli
was even smaller than that in nucleoplasm at 37◦C (Figure
3B). These findings strongly suggest that some components
in the nucleolus associate with topo II. We assume that
RNA might be one of the major candidates. To test this,
HEK cells transfected with WT-EGFP were permeabilized
with digitonin and treated in situ with RNase A or DNase
I. The specificity and completeness of digestion was con-
firmed by agarose gel electrophoresis (Supplementary Fig-
ure S2A). The nucleolar localization of WT-EGFP did not
change by permeabilization or DNase treatment. However,
RNase digestion resulted in relocation of EGFP signal from
nucleoli to nucleoplasm (Supplementary Figure S2B), sug-
gesting that nucleolar retention of topo II is mediated pri-
marily through RNA–topo II interactions.
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Figure 3. Cold-induced translocation of topo II from nucleolus to nucleoplasm is accounted for by its lowered catalytic rate. (A) Simultaneous record-
ings of medium temperature and nuclear distribution of topo II-EGFP expressed in HEK cells. Medium temperature was varied using an on-stage
heating/cooling device and monitored by a thermocouple thermometer. Images were recorded at 1-min intervals for 60 min. Scale bar, 5 m. (B) HEK
cells transfected with topo II-EGFP were subjected to FRAP analysis either at 37◦C or at 18◦C. Fluorescence images were recorded after bleaching the
circled areas in nucleoplasm or nucleolus. Representative images and recovery curves (fluorescence relative to pre-bleach) are shown. Plotted in the bar
graph are binding times in seconds that were calculated from kinetics data of 24 nuclei for each condition using ImageJ 1.4.6. Bars, mean/SD (n= 24); **P
= 1.8 × 10−17, *P = 6 × 10−3 by Student’s t-test. Scale bar, 5 m. (C) Temperature dependency of relaxation products in on-bead assay: enzyme-bound
versus released DNAs. DNA bands in each lane were quantified by densitometry and relative amounts at each temperature were graphed. Note that the
DNA in unbound fraction is fully relaxed at 15◦C, but remained supercoiled at 0◦C.
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Figure 4. Migratory behavior of functionally defective topo II mutants expressed in nucleus that are tagged with EGFP at C-terminus. (A) Summary of
amino acid changes introduced to WT topo II. (B) Assessment of in vivo topo II activity by the band depletion assay. Activities for endogenous enzyme
(labeled topo II) and EGFP-fused exogenous one (topo II-EGFP) can be discriminated by the size difference. EGFP-fused mutants are abbreviated: GI,
G173I; LF, L178F; YS, Y814S. (C) Changes in the nuclear distribution of topo IImutants after ICRF-193 treatment. Shown here are EGFP fluorescence
images (upper panel; scale bar, 5 m) and the ratio of nucleolar fluorescence to whole nuclear fluorescence (lower graph). The ratio was determined by
using the ‘threshold’ and the ‘integrated density (IntDen)’ functions of ImageJ software. Bars, mean/SD (n = 50).
A novel domain in the C-terminal region of topo II is in-
volved in nucleolar retention
RNA interactions with a DNA-binding protein like topo II
may be due to non-specific binding activity to a polyanion
scaffold. The likelihood of a non-specific, non-physiological
artifact is reduced if binding is selectively mediated by spe-
cific protein domains. To examine the domains responsi-
ble for topo II–RNA interaction and nucleolar prefer-
ence, we prepared topo II deletion mutants and examined
their nuclear localization together with RNA-binding abil-
ities in vitro. The canonical CTD of human topo II starts
from amino acid residue #1202 and ends at the C-terminus
#1621 (38) that corresponds to rat topo II #1195–1614.
In this study, the rat enzyme was simply divided into two
portions, a C-terminal segment (CTD, #1201–1614) and
its complementary segment (CTD, #1–1199), which con-
tains the ATPase domain, dimerization domain and DNA-
binding/cleavage core. TheCTD’ (#1251–1614),missingN-
terminal 50 residues of CTD, is equivalent to the human
topo II #1258–1621 that contains three NLSs and is capa-
ble of transferring a marker protein (-galactosidase) into
nuclei (17). WT enzyme and the truncation mutants were
dually tagged with Flag on N-terminus and EGFP on C-
terminus, and expressed in HEK cells (Figure 5A).
Tagged proteins were pulled down with anti-Flag
antibody-coated magnetic beads, followed by incubation ei-
ther with total RNA, poly (A)− RNA, or poly (A)+ RNA
isolated from HEK cells. The WT topo II bound RNA
regardless of poly (A) tails (Figure 5B). Both CTD and
CTD retained the RNA-binding activity, although bound
RNA levels were lower than those of WT. As shown in Fig-
ure 5B (center panel), CTD’ did not bind poly (A)− RNA,
whereas the mutant did bind poly (A)+ RNA (Figure 5B,
right panel), indicating that the N-terminal 50 residues of
CTD are required for the binding of poly (A)− RNA.
Correlations between RNA-binding activity and cellu-
lar localization of these mutants were analyzed. Although
CTD binds to both poly (A)− and poly (A)+ RNAs, this
mutant was localized exclusively in cytoplasm most likely
due to the absence of an NLS (Figure 5C). Just like the WT
enzyme, the EGFP signal for CTD localized in nuclei with
nucleolar enrichment. However, CTD’ did not accumulate
in nucleoli, although the mutant exclusively localized in nu-
clei. This observation agrees with the previous report (17).
The EGFP-tagged SV40 NLS showed similar localization
pattern (Figure 5C). These data suggest that NLS alone is
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Figure 5. RNA-binding ability and cellular localization of topo II domain-deletion mutants. (A) Domain diagram of deletion mutants used in this
experiment that are dually tagged with Flag/EGFP. Amino acid sequence for CRD (C-terminal regulatory domain) and its subdomains (boxed) are given
in the middle. (B) Binding of cellular RNA fractions with topo II deletion mutants immobilized on magnetic beads. Plotted data are expressed in mean
with SD (n = 4). (C) Cellular localization of topo II deletion mutants. EGFP images are shown along with differential interference contrast (DIC)
images. Images for the SV40 NLS (PKKKRKV) cloned in pEGFP-N1 are put on the right as a control. Scale bars, 5 m. (D) Localization of CRD in
intact, digitonin-treated and digitonin/RNase-treated cells (upper panel). The subdomains boxed in A were further deleted from CRD and their cellular
localizations were examined (lower panel). EGFP images are shown along with DIC images. Scale bars, 5 m.
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not sufficient for the nucleolar accumulation and the region
(#1201–1250) is essential for the topo II CTD to accumu-
late in nucleoli and for its binding to RNA.
Since this 50-residue domain appears to have a prime im-
portance in the enzyme’s transactions, we refer to this do-
main as the CRD (or ‘C-terminal regulatory domain’) and
performed further analyses by expressing CRD in HEK
cells as an EGFP-tagged protein (Figure 5D). The local-
ization pattern of CRD was similar to that of WT and
CTD, being exclusively in nuclei with nucleolar accumula-
tion (Figure 5D, upper panel). Also like the WT-EGFP, the
CRD-EGFP relocated from nucleoli to nucleoplasm upon
in situ digestion with RNase in digitonin-permeabilized
cells. Thus, nucleolar retention of CRD may be mediated
by its binding to RNA in nucleoli.
CRD contains some characteristic sequence motifs
within lysine clusters on both ends (Figure 5A). The #1201–
1215 region is composed of regularly spaced repeats of ly-
sine (K) and small hydrophobic residues: glycine (G), ala-
nine (A) or valine (V), which is termed here Phi-K mo-
tif. The #1247–1250 region contains four consecutive ly-
sine residues (K-stretch). When Phi-K motif was deleted
from CRD (Phi-K motif), the EGFP signal distributed
diffusely throughout the cell (Figure 5D, lower panel). Dele-
tion of K-stretch (K-stretch) from CRD did not affect
its nuclear localization, whereas its nucleolar accumulation
was almost lost, suggesting that the K-stretch is indispens-
able for nucleolar localization of CRD. When both Phi-K
motif and K-stretch were deleted from CRD, the mutant
distributed in cytoplasm. These results clearly indicate that
Phi-Kmotif is responsible for the nuclear retention and that
Phi-K motif and K-stretch cooperate together for the accu-
mulation of CRD in nucleoli.
CRD regulates enzymatic activity of topo II through RNA
binding
The function of CRD was further examined using topo II
deletion mutants illustrated in Figure 6A. The CTD’ is
a truncation mutant lacking CTD’. The WT and mutant
enzymes were Flag-tagged on their N-termini, expressed in
HEK cells and immunopurified with anti-Flag antibody.
Purified proteins were subjected to relaxation assay with su-
percoiled plasmid DNA. Topo II released from antibody
beads showed similar relaxation activities regardless of the
presence of deletion (Supplementary Figure S3A and B).
We showed previously that relaxation activity of topo II
was inhibited by cellularRNA (23). As expected, total RNA
purified from HEK cells inhibited the relaxation of Flag-
tagged WT topo II, whereas that of CTD was not in-
hibited at all (Figure 6B). Remarkably, however, RNA did
inhibit the reaction with CTD’. Therefore, we examined
whether topo II lacking only CRD (CRD) was resistant
to RNA and found that this is indeed the case. To confirm
the resistance of CRD to RNA, enzyme inputs were var-
ied in a dilution series keeping the RNA amount constant
(Supplementary Figure S4A). These data show that relax-
ation activity was essentially independent of enzyme/RNA
ratios.
When the inhibition experiments were repeated under the
same conditions using RNA samples fractionated into poly
(A)− and poly (A)+ RNAs, we obtained basically the same
results with unfractionated total RNA. Thus, CRD is very
likely responsible for the regulation of enzyme activity me-
diated by RNA regardless of poly (A) tailing.
CRD is involved, but not essential, in the processivity of topo
II
The use of a bead-bound topo II assay allowed us to assess
the topological status of substrate DNA that is free versus
enzyme bound. Negatively supercoiled DNA was relaxed
by the immobilized WT or mutant topo II in the presence
of increasing RNA inputs (Figure 6C). Without RNA, WT
enzyme did not release the product until DNA was fully re-
laxed, reflecting the processive nature ofWT enzyme. To see
whether CRD contributes to the processivity, topo II mu-
tants were compared. When incubated at 30◦C, it appeared
that CRD has little contribution to the processive mode of
reaction sinceCTD’ that contains CRD did not hold par-
tially relaxed DNA, while CRD did (Figure 6C). How-
ever, when the reaction was performed at lower tempera-
tures (to reduce catalytic rates), CTD’ did retain the in-
termediate products (Figure 6D, lower panel). In contrast,
CTD did not bind partially relaxed DNA even at lower
temperatures (Figure 6D, upper panel), or at decreased ac-
tivity with lessCTDprotein (Supplementary Figure S4B).
The results indicate that without CTD, topo II–DNA in-
teraction is highly distributive, viz. non-processive.
Thus, CRD appears to be involved, but not essential, in
the processive reaction and the CTD’ is more likely respon-
sible for processivity of topo II through retention of par-
tially relaxed DNA. The binding or retention of these in-
termediate products is inhibited by increasing RNA inputs
(Figure 6C).
CRD assists the RNA-mediated inhibition of supercoiled
DNA binding to topo II
Previous studies on topo II–DNA interactions demon-
strated that the enzyme prefers to bind crossovers between
duplex DNA segments, which occur frequently in super-
coiled conformation (39,40). More recent studies suggested
the involvement of CTD in capturing the G-segment that
is strongly bent between the paired winged-helix domains
(41,42). Little biochemical knowledge is available, however,
concerning the DNA-binding properties of topo II relative
to supercoils. We took advantage of the on-bead assay to
investigate the binding of DNA and effects of RNA on the
binding in the absence of ATP. Without ATP, the enzyme
would behave like a simple DNA binder with constitutively
open N-gate.
DNA-binding reaction was first optimized by incubating
equimolar mixtures of negatively supercoiled (form I) and
linear (form III) DNAs with constant amount of immo-
bilized WT-topo II (Supplementary Figure S5). The en-
zyme bound supercoiled DNA preferentially as total DNA
amounts increase to a saturation level, but both forms were
equally bound 100% at a lower dosage (5 ng each). Under
the latter conditions, competitive binding assay was per-
formed with WT and deletion mutants (Figure 7A). All
mutants showed preference toward supercoiled DNA over
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Figure 6. Effects of RNA on the relaxation activity of topo II domain-deletion mutants. (A) Domain structure of deletion mutants used here that are
Flag-tagged on N-terminus (not shown in the figure). (B) Inhibitory effects of total RNA on the relaxation activity. Tag-purified topo II and the domain
mutants (20 fmol) were incubated with 5 ng of supercoiled pUC18 DNA. Increasing amounts of RNA (5, 50, 500 ng) were added to the reaction. Positions
of supercoiled form (I) and relaxed form (Ir) DNA are indicated on the right. (C) Fractionation of relaxation intermediates into enzyme-bound and
released DNA by using 80 fmol immobilized topo II domain mutants (on-bead assay). After incubation with 5 ng of supercoiled DNA as described in
‘Methods’ section, product DNAwas fractionated into ‘bound’ and ‘unbound’ bymagnetic separation. (D) Effects of reaction temperature on the retention
of relaxation intermediates on the enzyme. DNA in unbound fraction indicates that the supercoiled substrate remained almost unreacted at 0◦C, but no
unreacted substrate remained at 15◦C. Difference in the ladder position between 15 and 37◦C is due to the temperature-dependent alteration of the writhe
for relaxed form (Ir). Results for the WT enzyme are shown in Figure 3C.
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Figure 7. DNA-binding assays of Flag-tagged topo II domain-deletion mutants in the absence of ATP. (A) Competitive binding of supercoiled (form I)
and linear (form III) DNA to the enzyme (80 fmol) immobilized on beads. After incubating equimolar mixture (5 ng each) of supercoiled and linear DNA
with the beads, bound and unbound DNA was fractionated by magnetic separation. DNA amounts in agarose gel bands were quantified by densitometry
and plotted in the graph as percentages of input DNA (n= 3). (B) Effects of RNA onDNA binding. Five nanograms of supercoiled and linear DNAs were
incubated separately with the enzyme (80 fmol). RNA was added as in Figure 6C. (C) Relative amounts of bound DNA as determined by densitometry of
the gel images shown in (B). Supercoiled or linear DNA amounts bound to WT enzyme in the absence of RNA were set to 100%. Data points are mean
with SD bar (n = 5). Asterisks indicate a significant deviation from CTD (P < 0.005).
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linear DNA, although with reduced overall affinity. Re-
duction of DNA-binding ability was also reported with
enzyme–oligonucleotide interactions when C-terminal re-
gion (#1264–1621) was deleted from human topo II (43).
The deleted region corresponds to #1257–1614 of rat topo
II. Deletion of CTD (CTD) significantly decreased lin-
ear DNA binding. Adding back either CRD or CTD’ how-
ever restored binding to 50–60%.Without CTD’, CRDwas
essential for linear DNA binding.
Similar results were obtained when supercoiled and lin-
ear DNAs were incubated separately (Figure 7B, leftmost
lanes). The data clearly indicate that CTD, including CRD,
is not essential for supercoiled DNA binding, but CTD’ as-
sists the binding. In contrast, CTD is essential for linear
DNA binding (Figure 7C, right panel) and mutants har-
boring either CRD or CTD’ retained linear DNA-binding
activity with reduced levels, suggesting that CRD alone re-
tains the ability to bind linear DNA.
In the presence of RNA, binding of supercoiled DNA
to CTD decreased slightly in a dose-dependent manner
(Figure 7B and C), although the change was statistically in-
significant (P > 0.10). In contrast, the RNA inhibition was
significant (P < 0.01) when topo II contains CRD (com-
pare CTD and CTD’). Similarly, CRD was less sus-
ceptible to RNA compared to WT (P < 0.01). Thus, CRD
appears to be a principal element for the RNA interference
on the association between topo II and supercoiled DNA.
Importantly, this parallels the effects of RNA on catalytic
activity (Figure 6). As for linearDNA,RNA strongly inhib-
ited both CRD- and CTD’–DNA interactions (Figure 7C,
right panel).
These data suggest that supercoiled DNA is recognized
by and bound to the N-terminal catalytic core (CTD) that
contains minimal topo II activities of ATPase and DNA
binding/cleavage. The consecutive short-segment, CRD, is
not required for the supercoiled DNA binding, but it regu-
lates the association between the enzyme core and substrate
DNA by an RNA-mediated mechanism, probably through
direct interaction with RNA. Taken together, CRD is a crit-
ical domain that controls topo II activity by conferring its
susceptibility to RNA and directionality toward nucleolus.
DISCUSSION
Subnuclear localization and catalytic activity of topo II are
linked
Topo II in interphase nuclei was reported to be highly
mobile and free to exchange between nuclear subcompart-
ments (21). The enzyme relocates from nucleoli to nucleo-
plasm upon stabilizing the catalytic intermediates, indicat-
ing that it is most actively engaged in DNA catalysis in nu-
cleoplasm. The notion is in good agreement with our pre-
vious observation that in differentiating neuronal cells, a
large proportion of topo II is involved in catalytic action
and distributed in nucleoplasm, whereas inmature neuronal
cells the enzyme is concentrated in nucleoli and has a lim-
ited access to chromatin DNA, although isolated enzyme is
fully active on plasmid DNA in vitro. (9,10).
Using topo II mutants, we have directly demonstrated
in this study that enzymatically incompetent topo II ac-
cumulates in the nucleolus. In ATP-depleted cells, both en-
dogenous and EGFP-fused topo II are exclusively nu-
cleolar. The G173I mutant lacking ATP-binding activity
was exclusively nucleolar when expressed in HEK cells. We
also showed that nucleoplasmic topo II is the catalyti-
cally active form. Topo II clamped around target DNA
by ICRF-193 treatment distributed predominantly in nucle-
oplasm. As expected, enzymatically incompetent topo II
(the G173I mutant andWT topo II in ATP-depleted cells)
did not change the nucleolar localization even after ICRF-
193 treatment. The inactive tyrosine mutant, Y814S, was
most likely immobilized on chromatin by the N-terminal
clamp and thus heavily enriched in the nucleoplasm.
To our knowledge, the reversible translocation of topo
II induced by temperature has not been previously de-
scribed. FRAP experiments and DNA relaxation with im-
mobilized enzyme reveal that this effect is due to slower cat-
alytic rates of topo II at suboptimal temperatures, which
results in prolonged residence time in nucleoplasm in living
cells.
RNA is a major determinant of topo II localization in nu-
cleoli
The binding time of topo II at 37◦C estimated fromFRAP
was much longer in nucleoli than in nucleoplasm (Figure
3B), which is in good agreement with Christensen et al.
(21). They further showed later using a mathematical dis-
tribution model with simple differential equations that nu-
clear topo II can be distinguished between free and bound
fractions, indicating a higher proportion of bound form
in nucleoli than in nucleoplasm (37). Whereas the binding
time for nucleoplasmic topo II increased remarkably at
lower temperatures because of its decreased turnover rate
on DNA, the binding time in nucleoli did not increase sig-
nificantly (Figure 3B), indicating that the enzyme is not in-
teracting with DNA. Therefore, the putative binding part-
ner(s) of topo II in nucleoli is unlikely to be genomic DNA
(presumably ribosomal DNA repeats).
Salt extraction experiments with whole cells indicated
that the interaction between topo II and cellular compo-
nents is stable in 0.12 M NaCl, but disrupted in 0.42 M
NaCl, suggesting the ionic nature of this interaction (data
not shown). Furthermore, treatment of permeabilized cells
with RNase, but not DNase, resulted in the relocation of
topo II-EGFP from nucleoli to nucleoplasm (Supplemen-
tary Figure S2B). We have also presented more direct evi-
dence for the binding of cellular RNA with topo II that
is immobilized on magnetic beads (Figure 5B). These data
suggest that RNA or an RNA-containing complex is a ma-
jor holding element of topo II in nucleoli that contributes
to the prolonged residence of the enzyme in nucleoli.
Identification of a new domain in CTD that mediates topo
II–RNA interactions and nucleolar localization
EGFP-fused CTD expressed in HEK293 cells localized
exclusively in nuclei with enhanced targeting to nucleoli.
CTD’-EGFP, however, localized predominantly to nucleo-
plasmic regions (and was depleted from nucleoli). The hu-
man counterpart of CTD’ fragment that contains multi-
ple NLSs also localizes in nucleoplasm but not in nucle-
oli (17). It appears, therefore, the N-terminal 50 residues of
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CTD (CRD) are indispensable for nucleolar accumulation
of CTD.
The CRD is located in a region predicted to be intrinsi-
cally disordered (Supplementary Figure S6A). However, its
sequence is highly conserved among rat, mouse and human
topo II, but diversified from topo II (Supplementary Fig-
ure S6B). EGFP-fused CRD is small enough to passively
diffuse into nuclei. For nuclear retention of CRD, the ‘Phi-
K motif ’ composed of a 15-amino acid stretch with alter-
nating Lys and hydrophobic amino acids seems to be essen-
tial (Figure 5D). The Phi-Kmotif, however, does not behave
like a functionalNLS sinceCTD’-EGFP that contains the
Phi-K motif but not a canonical NLS localized predomi-
nantly in cytoplasm (data not shown). CRD also contains
a stretch of four Lys residues (termed K-stretch) that was
necessary, but not sufficient for nucleolar accumulation of
CRD, which required both Phi-K motif and K-stretch.
Experimental validation of nucleolar localization signals
(NoLSs) revealed that NoLSs are mainly comprised of a
stretch of basic residues (Arg or Lys) and are localized in
regions predicted to be -helices or coils (44). Secondary
structure of CRD around Phi-K motif and K-stretch pre-
dicted by Jpred 3 (45) did not contradict this view. Thus,
the Lys-rich regions in CRD (Phi-K motif and K-stretch)
are likely to function together as a NoLS also in full-length
topo II.
Unlike the nucleus and other membrane-bound or-
ganelles, there is no membrane separating the nucleo-
lus from the surrounding nucleoplasm; thus, any soluble
molecule could diffuse in and out of the nucleolar com-
partment. Targeting of a specific molecule to the nucleolus
requires direct or indirect interaction with one of the nu-
cleolar building blocks composed of rDNA, its transcripts,
small nucleolar RNAs and a number of ribosomal/non-
ribosomal proteins (46). A short stretch of positively
charged amino acids of human T-cell leukemia virus Rex
proteins that localize in nucleoli contributes to the bind-
ing of Rex to its target RNA (47). An Arg/Lys-rich pep-
tide derived from TRBP, a cellular protein that binds HIV-1
trans-activation responsive (TAR)RNA, was necessary and
sufficient to ensure binding to the upper-stem/loop site of
TAR that contains a double-stranded RNA (dsRNA). The
Arg/Lys-rich peptide of TRBP is composed of 15 amino
acid residues with alternations of Lys/Arg and hydropho-
bic amino acid stretches (48). The dsRNA elements can be
formed by base pairing of complementary sequences within
primary RNA transcripts. Based on these reports and our
current results, we speculate that topo II stays in nucleoli
through interaction between CRD and nucleolar RNA.
CRD is an essential element for RNA-mediated regulation of
topo II activity
The CTD-truncated mutant (CTD) was catalytically as
active as full-length topo II (15). However, CTD was es-
sential for the RNA-mediated inhibition of topo II cat-
alytic activity. We have shown previously that relaxation
of supercoiled DNA by full-length topo II was inhibited
by cellular RNA (23). In the present study, it became clear
that the RNA inhibition is abolished by truncation of CTD.
A responsive element of the RNA-mediated inhibition was
Figure 8. Summary for relative contributions of topo II functional do-
mains. (A) Domains involved in the activities shown on the left are shaded.
Dark shade and light shade represent full and partial contribution, respec-
tively. (B) RNA-mediated inhibition. Inhibitory domains are shaded de-
pending on their relative contributions as in (A). Domains pointed by ar-
rowhead are inhibited domains. Solid line and broken line designate the
strong and weak inhibitions, respectively. Form I, supercoiled DNA; Form
III, linear DNA.
more finelymapped to CRD, since relaxation of supercoiled
DNA by CRD-deleted mutants (CTD and CRD) was
insensitive to RNA, whereas the relaxation by the CRD
containing mutant (CTD’) was inhibited.
To understand the molecular mechanism of RNA-
mediated regulation of topo II through CRD, we com-
pared DNA binding of immobilized topo II with super-
coiled (form I) and linear (form III) targets in the absence
ofATP. Themodel shown in Figure 8A andBwill be helpful
for understanding the following discussions. Without ATP,
N-gate of the enzyme is supposed to be open and super-
coiledDNAwill not be relaxed (49,50). Full-length topo II
can bind with both supercoiled and linear DNA with pref-
erence to supercoils (Figure 7A and Supplementary Figure
S5), which is consistent with the notion that eukaryotic type
II topos prefer supercoiled substrates because DNA cross-
ings are more prevalent in superhelical DNA compared to
unconstrainedDNA (39,40,50,51). All themutants we stud-
ied bound supercoiled DNA, although the ability decreased
somewhat whenCTDorCTD’was deleted. To our surprise,
in contrast to supercoiled DNA, linear DNA did not bind
to the CTD mutant (both CTD’ and CRD were deleted),
although it retained binding activity to supercoiled DNA.
These data suggest that supercoiled DNA binds to the
core region of topo II as an initial step and the CTD fa-
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cilitates this binding. Inhibitory effects of RNA on super-
coiled DNA binding to topo II mutants resembled those
on DNA relaxation activity of the mutants. This implies
that the binding of RNA with CRD inhibits the interac-
tion of supercoiled DNA substrate with the core region, re-
sulting in the inhibition of relaxation (Figure 8B). The in-
hibition appears to be non-competitive in nature and CRD
behaves like a built-in RNA-responsive element for the reg-
ulation of topo II activity. Similarly, inhibitory effects of
RNA on linear DNA binding to topo II mutants resem-
bled those on DNA capture by the enzyme during catalysis
(Figure 8B). The CTD-truncated topo II does not bind
linear DNA and lacks the ability to hold partially relaxed
DNA, suggesting that interaction between CTD and sub-
strate DNA is required for the retention of G-segment dur-
ing the relaxation in a processive mode. RNA may, thus,
interfere with the DNA retention by binding competitively
to CTD (especially to CTD’ portion).
Although crystallographic information on CTD is not
available at present, it would be possible to extrapolate the
position of CRD relative to the known structure because
CRD resides right next to the C-terminus of the crystal-
ized fragments (3,38,42,52). CTD’ may protrude away from
the core region of topo II and involve in holding the G-
segment to drive the enzyme toward processive mode. How-
ever, CRD is probably placed close to the DNA gate and
the active site tyrosine, thus regulating cleavage reaction
more or less directly through interaction with RNA. Future
studies on CRD structure would help clarify matters. The
topo II CRD and corresponding region of topo II are
not highly homologous, although they share some features
in common (Supplementary Figure S6B). It is not known
whether this region in topo II serves as a functional coun-
terpart of topo II CRD.
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